

**Form 51-102F3**  
**Material Change Report**

**1. Name and Address of Company**

**Treatment.com AI Inc.**  
700-838 W Hastings Street  
Vancouver, BC V6C 0A6

(the "Company")

**2. Dates of Material Change(s)**

March 13, 2025

**3. News Release(s)**

A news release was issued on March 13, 2025 and disseminated via Globe Newswire pursuant to section 7.1 of National Instrument 51-102.

**4. Summaries of Material Changes**

The Company is pleased to announce it has closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the "Offering") with Ventum Capital Corp., (the "Underwriter"). Pursuant to the Offering, the Company issued 6,600,000 units (the "Units") at the issue price of \$0.50 per Unit for gross proceeds of \$3,300,000. Each Unit consists of one common share in the capital of the Company (a "Share") and one-half of one Share purchase warrant of the Company (each whole warrant being, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Share at the exercise price of \$0.75 until March 13, 2027. Pursuant to the Underwriting Agreement, the Company paid to the Underwriter a cash commission of \$264,000 and issued 528,000 non-transferable broker warrants (the "Broker Warrants"). Each Broker Warrant is exercisable for one Unit at the price of \$0.50 until March 13, 2027.

**5. Full Description of Material Changes**

News Release dated March 13, 2025 – See Schedule "A"

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**7. Omitted Information**

No information has been omitted.

**8. Executive Officer**

Dr. Essam Hamza, CEO of the Company, is knowledgeable about the material change contained herein and may be reached at (612) 788-8900.

**9. Date of Report**

This report is dated March 13, 2025.

**SCHEDULE "A"**  
to the Material Change Report March 13, 2025

**TREATMENT.COM AI INC. ANNOUNCES CLOSING OF  
UPSIZED BROKERED LIFE OFFERING OF UNITS**

**Vancouver, British Columbia, March 13, 2025** – Treatment.com AI Inc. (the "**Company**" or "**Treatment**") (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news releases dated February 27, 2025 and March 3, 2025, it has closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the "**Offering**") with Ventum Capital Corp., (the "**Underwriter**") who acted as underwriter pursuant to an underwriting agreement dated March 13, 2025 (the "**Underwriting Agreement**").

Dr. Essam Hamza, the Chief Executive Officer of Treatment, added: "We would like to thank the shareholders for the strong demand shown for this financing. I would also like to thank the teams at Ventum and Treatment for all the hard work they have put into getting this significant deal across the finish line. The added money will help us expedite our ambitious growth plans and we look forward to updating the market accordingly."

Pursuant to the Offering, the Company issued 6,600,000 units (the "**Units**") at the issue price of \$0.50 per Unit for gross proceeds of \$3,300,000. Each Unit consists of one common share in the capital of the Company (a "**Share**") and one-half of one Share purchase warrant of the Company (each whole warrant being, a "**Warrant**"). Each Warrant entitles the holder thereof to purchase one Share at the exercise price of \$0.75 until March 13, 2027.

The Offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 *Prospectus Exemptions* (the "**Listed Issuer Financing Exemption**") and therefore the Units issued pursuant to the Offering are not subject to a hold period in accordance with applicable Canadian securities laws. There is an amended and restated offering document (the "**Offering Document**") related to the Offering that can be accessed under the Company's profile at [www.sedarplus.ca](http://www.sedarplus.ca) and on the Company's website at [www.treatment.com](http://www.treatment.com). Prospective investors should read this Offering Document before making an investment decision.

The Company intends to use the proceeds from the Offering for sales and administrative expenses, software research and development and working capital purposes.

Pursuant to the Underwriting Agreement, the Company paid to the Underwriter a cash commission of \$264,000 and issued 528,000 non-transferable broker warrants (the "**Broker Warrants**"). Each Broker Warrant is exercisable for one Unit at the price of \$0.50 until March 13, 2027. The Broker Warrants and the underlying securities issued to the Underwriter will be subject to a four month and one day hold period in accordance with Canadian securities laws.

The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of

an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

**About Treatment.com AI Inc.**

*Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment's products and services: [www.treatment.com](http://www.treatment.com) or email: [info@treatment.com](mailto:info@treatment.com)*

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO

[ehamza@treatment.com](mailto:ehamza@treatment.com)

For media inquiries, contact: [media@treatment.com](mailto:media@treatment.com)

Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955